Assembly Biosciences
Open
$26.61
Prev. Close
$26.61
High
$26.86
Low
$26.61
Market Snapshot
$416.47M
-68.0
-6.72
73
Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2010-12-17. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. The company is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
emptyResult
Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2010-12-17. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. The company is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Recently from Cashu
U.S. Intervention Highlights Iran's Supreme Leadership Transition and Its Geopolitical Implications
Titular Transition: A Turning Point for Iran's Supreme Leadership As the Assembly of Experts in Iran prepares to confirm a new supreme leader, the political landscape in the region is underscored by g…
Impending Supreme Leader Selection in Iran Raises Stakes for U.S.-Iran Relations
Impending Leadership Transition at the Heart of Iran's Governance The Assembly of Experts in Iran is poised to confirm a new supreme leader, an event that carries significant ramifications not only fo…
California Voter ID Initiative Gains Bipartisan Support Amid Controversial Electoral Reform Debate
California’s Voter ID Initiative Gains Momentum Amid Bipartisan Support The "California Voter ID Initiative," led by the political activism group Reform California, emerges as a pivotal movement, amas…
Iran's Leadership Crisis: Risks for Global Health Policy and Biotechnology Sector
Impact of Leadership Vacuum in Iran on Global Health Policy In the wake of the recent U.S. and Israeli airstrikes that led to the assassination of Iran's Supreme Leader Ayatollah Ali Khamenei, the pol…